california dmhc glp-1 coverage exclusion allowed 🚨 Alert: for Obesity Medications at Risk Just two years after Medi-Cal began covering FDA-approved medications for obesity, that coverage is set to end in January 2026 — a GLP-1 CARVE OUTS AND MENTAL

In contrast, Samples K and B (421.06 and 427.91 kcal/100 g, respectively), while slightly lower in energy density, still provide adequate caloric support for athletes with moderate energy requirements or those engaged in less demanding training regimens

Lets discuss

Remarkably, all 12 patients reported significant improvement in symptoms and none reported adverse effects in the short term

Both medications follow predictable patterns, but the experience differs significantly between the two

Identity confirmation by mass spectrometry, purity assay, appearance check, and moisture content

www.fda.gov/Downloads/Drugs/Guidances/ucm071627